Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer’s disease treatment

Byeon, Seong Rim; Kim, Hyunjin Vincent; Jeon, Mijin; Ahn, Young Gil; Kim, Maeng Sup; Kong, Jae Yang; Kim, Young Soo; Kim, Dong Jin

doi:10.1016/j.bmcl.2013.02.104

Cited by 4 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic discoveries based on key course concepts were selected from the primary literature. For example, for the 2018 offering of the course, the following topics were selected: bolaamphiphilic vesicles (intermolecular interactions and amino acid/protein structure), novel Alzheimer’s treatments that cross the blood–brain barrier (membrane chemistry), the enantiospecific synthesis of heterocycles for breast cancer treatment (stereoisomers), acid-activated antimicrobial copolymers (acids and bases), and RNA-binding scaffolds for HIV-1 Rev inhibition (molecular genetics) . Students generally worked in teams of 4 for each project.…”

Section: Course Structure and Contentmentioning

confidence: 99%

Science and Business of Medicinal Chemistry: A “Bench-to-Bedside” Course for Nonmajors

et al. 2019

View full text Add to dashboard Cite

The Science and Business of Medicinal Chemistry" was developed to provide nonscience majors with an in-depth perspective into the pharmaceutical industry. As a lecture course with a laboratory component, topics discussed include an introduction to the basic concepts of medicinal chemistry, such as drug discovery, development, and commercialization; a discussion of chemical bonding and the organic functional groups found in drug molecules; and an examination of the physiochemical properties related to drug action. Student scientific literacy of the public policy debates surrounding the pharmaceutical industry and the commercialization of science was enhanced through class discussions and group-based projects. The details of this course, its implementation, and assessment are discussed.

show abstract

Section: Course Structure and Contentmentioning

confidence: 99%

Science and Business of Medicinal Chemistry: A “Bench-to-Bedside” Course for Nonmajors

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Excellent papers on A␤ aggregation inhibitors from universities were presented: 2013: [535][536][537][538][539][540][541][542], 2014: [543][544][545]922].…”

Section: Khg-26377mentioning

confidence: 99%

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Froestl

Pfeifer

Muhs

2014

JAD

View full text Add to dashboard Cite

Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers, are very productive. The review "Drugs interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs" was accepted in October 2012. In the last 20 months, new targets for the potential treatment of Alzheimer's disease were identified. Enormous progress was realized in the pharmacological characterization of natural products with cognitive enhancing properties. This review covers the evolution of research in this field through May 2014.

show abstract

Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development

Cacabelos

Torrellas

et al. 2014

Methods in Molecular Biology

165

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a major problem of health and disability, with a relevant economic impact on our society. Despite important advances in pathogenesis, diagnosis, and treatment, its primary causes still remain elusive, accurate biomarkers are not well characterized, and the available pharmacological treatments are not cost-effective. As a complex disorder, AD is a polygenic and multifactorial clinical entity in which hundreds of defective genes distributed across the human genome may contribute to its pathogenesis. Diverse environmental factors, cerebrovascular dysfunction, and epigenetic phenomena, together with structural and functional genomic dysfunctions, lead to amyloid deposition, neurofibrillary tangle formation, and premature neuronal death, the major neuropathological hallmarks of AD. Future perspectives for the global management of AD predict that genomics and proteomics may help in the search for reliable biomarkers. In practical terms, the therapeutic response to conventional drugs (cholinesterase inhibitors, multifactorial strategies) is genotype-specific. Genomic factors potentially involved in AD pharmacogenomics include at least five categories of gene clusters: (1) genes associated with disease pathogenesis; (2) genes associated with the mechanism of action of drugs; (3) genes associated with drug metabolism (phase I and II reactions); (4) genes associated with drug transporters; and (5) pleiotropic genes involved in multifaceted cascades and metabolic reactions. The implementation of pharmacogenomic strategies will contribute to optimize drug development and therapeutics in AD and related disorders.

show abstract

Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer’s disease treatment

Cited by 4 publications

References 19 publications

Science and Business of Medicinal Chemistry: A “Bench-to-Bedside” Course for Nonmajors

Science and Business of Medicinal Chemistry: A “Bench-to-Bedside” Course for Nonmajors

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development

Contact Info

Product

Resources

About